Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.47 |
| ▸ | JAK2 | O60674 | 15/20 | 0.43 |
| ▸ | TYK2 | P29597 | 13/20 | 0.43 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970551 | 1.00 | JAK1 (0.47) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL15970253 | 0.89 | JAK2 (0.46) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL15970254 | 0.89 | JAK2 (0.46) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL29838827 | 0.89 | JAK1 (0.58) | JAK1JAK2JAK3GPR119 | |
| SCHEMBL18419034 | 0.88 | JAK1 (0.48) | JAK1JAK2JAK3GPR119 | |
| SCHEMBL17500887 | 0.87 | JAK1 (0.49) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL17500886 | 0.87 | JAK1 (0.49) | JAK1JAK2TYK2JAK3GPR119 | |
| SCHEMBL15970166 | 0.84 | JAK2 (0.61) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL15970167 | 0.84 | JAK2 (0.61) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL15970513 | 0.83 | JAK1 (0.49) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966980-B2 | Pyrrolo[2,3-d]pyrimidine derivatives | PFIZER INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3180344-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | PFIZER (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3290421-B1 | COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-3290421-A1 | COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | Pfizer Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2958921-B1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK) | PFIZER (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3180344-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9549929-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545405-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160045508-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2016024185-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | PFIZER INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20150246048-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. | 2015-09-03 | — | — | US | disclosed |
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. | 2015-08-13 | — | — | US | disclosed |
| US-9035074-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 13/4885 |
| US-20160045508-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 9/4885 |
| US-10966980-B2 | Pyrrolo[2,3-d]pyrimidine derivatives | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 9/4885 |
| US-20150246048-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 13/4885 |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.